- The program will focus on a PRAME-targeted TCR-engineered invariant natural killer T cell therapy to treat pediatric tumors.
- The program will receive around $1.1 million in funding to support its early-stage development.
- The agreement provides for a double-digit share of future commercial revenues.
Shares of MiNK Therapeutics (INKT) gave up most of their early gains to trade 32% higher on Tuesday after the company announced a collaboration with the C-Further, an oncology consortium, to develop a cell therapy targeting pediatric cancers.
The program will focus on a PRAME-targeted TCR-engineered invariant natural killer T (iNKT) cell therapy to treat pediatric tumors. Preferentially Expressed Antigen in Melanoma, or PRAME, is a tumor antigen found in several cancers.
MiNK’s iNKT platform aims to address key limitations of traditional cell therapies, which require patient-specific manufacturing and long preparation times.
The therapy is derived from healthy donors and can be produced in advance, stored, and delivered when needed without complex matching or intensive pre-treatment. This approach could allow faster treatment and broader access, especially for children with aggressive cancers, the company said.
Program To Receive $1.1 Million In Funding
By combining PRAME-targeting with MiNK’s iNKT cell platform, the therapy aims to precisely attack tumors while also activating broader immune responses.
The program will receive around $1.1 million in funding to support its early-stage development, and the agreement also provides for a double-digit share of future commercial revenues, the company added.
How Did Stocktwits Users React?
Retail sentiment for INKT on Stocktwits turned 'extremely bullish' from 'bullish' a day earlier, amid 'extremely high' message volumes.
One user saw support at $13.5.
Another user said the $1 million funding was a "small teaser" ahead of a potential buyout.
Year-to-date, the stock gained 24%.
For updates and corrections, email newsroom[at]stocktwits[dot]com